AstraZeneca PLC's (AZN) 澳洲幸运5官方开奖结果体彩网:🅷American depositary receipts (ADRs) fell more than 4% Thursday after the drug maker reported ﷽its profit was hurt by falling demand for COVID-19 treatments.

The Anglo-Swedish pharmaceutical firm reported fourth-quarter core earnings per share (EPS) of $1.45, short of forecasts. Revenue rose 7% to $12.02 billion, basically in line with 澳洲幸运5官方开奖结果体彩网:analysts' estimates.

For th♕e full year, core EPS was $7.26, with revenue up 3% to $45.81 billion. The compan♊y noted that revenue was negatively affected by slumping sales of COVID-19 vaccines and immune therapies (V&I), which reduced the total by $3.74 billion.

Fourth-quarter V&I revenue plunged 64% to $413 million 澳洲幸运5官方开奖结果体彩网:year-on-year (YOY) following “historic contracts” in 2022 for its Vaxzevria shot and monoclonal antibodies (mAbs) treatments. Sales of its “Other Medicines” category slipped 33% as its Nexium acid reflux pill faced generic competition in Japan.

Chief Executive Officer (CEO) Pascal Soriot remained optimistic, saying that the firm’s “differentiated and growing portfolio of approved medicines, global reach and rich R&D pipeline give us confidence that we will continue to deliver industry-leading gro🌳wth.”

AstraZeneca sees full-year core EPS and revenue increasing by a low-double-digit to a low-teens percentage at 澳洲幸运5官方开奖结果体彩网:constant exchange rates.

AstraZeneca ADRs🐎 were down 4.4% at $63.62 Thursday at around 1:45 p.m. E🌜T. The stock, which fell as low as $61.70 earlier in the session, reached its lowest level since October 2022.